8 recruiting, 5 active not recruiting, 5 completed, 1 not yet recruiting. 19 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Recruiting 8, Active not recruiting 5, Completed 5, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
Follow Imfinzi: new trials by email Literature Review of Imfinzi trials Research Report on Imfinzi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin - Biliary Tract Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-04 | 2026-09-28 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Biospecimen Collection, Computed Tomography, Durvalumab - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 306 | 2025-04-01 | 2026-11-19 |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Biospecimen Collection, Cyclophosphamide, Doxorubicin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 3680 | 2023-11-27 | 2026-11-12 |
| A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) durvalumab - Biliary Tract Cancers | Phase 3 | Completed | AstraZeneca | 116 | 2023-07-21 | 2025-04-22 |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 474 | 2023-07-12 | 2026-08-17 |
| Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) Durvalumab, low-dose PCI - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Association NVALT Studies | 170 | 2021-12-06 | 2025-01-29 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 131 | 2021-11-12 | 2026-11-18 |
| Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features Pelvic external beam radiotherapy, Chemotherapy, Durvalumab - Endometrial Cancer | Phase 3 | Recruiting | Leiden University Medical Center | 316 | 2021-11-11 | 2026-10-08 |
| Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC Durvalumab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, NSCLC, Stage III | Phase 3 | Recruiting | Stanford University | 48 | 2021-08-25 | 2026-09-30 |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 712 | 2021-08-05 | 2026-06-04 |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab - Mesothelioma, Pleural Mesothelioma | Phase 3 | Completed | PrECOG, LLC. | 214 | 2021-02-18 | 2026-10-22 |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Durvalumab - Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 660 | 2020-04-29 | 2026-11-12 |
| Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment Durvalumab, Bevacizumab, Placebo - Hepatocellular Carcinoma | Phase 3 | Completed | AstraZeneca | 908 | 2019-04-29 | 2026-10-08 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Docetaxel, Durvalumab, Laboratory Biomarker Analysis - Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Phase 2 / Phase 3 | Completed | SWOG Cancer Research Network | 116 | 2014-07-31 | 2023-05-25 |
| Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Carboplatin, Cisplatin, Durvalumab - Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Phase 3 | Active not recruiting | Radiation Therapy Oncology Group | 330 | 2014-01-03 | 2026-06-08 |
Carcinoma, Non-Small-Cell Lung (6) · Lung Neoplasms (4) · Biliary Tract Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Liver Neoplasms (1) · Mesothelioma (1) · Mesothelioma, Malignant (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1)
National Cancer Institute (NCI) (6) · AstraZeneca (4) · NRG Oncology (2) · Association NVALT Studies (1) · ECOG-ACRIN Cancer Research Group (1) · Leiden University Medical Center (1) · PrECOG, LLC. (1) · Radiation Therapy Oncology Group (1) · SWOG Cancer Research Network (1) · Stanford University (1)
United States (15) · Canada (7) · France (4) · Germany (4) · Italy (4) · Netherlands (4) · Australia (3) · Brazil (3) · China (3) · Japan (3) · Poland (3) · South Korea (3) · Taiwan (3) · Thailand (3) · Turkey (Türkiye) (3)
Anna Nowak, MD (1) · Charles B Simone (1) · Deirdre J Cohen (1) · Dirk De Ruysscher, MD PhD (1) · Dwight H Owen (1) · Erin F Cobain (1) · Jean H Hoffman-Censits (1) · Jennifer Knox, MD (1) · Jennifer Y Wo (1) · Jeremy P Cetnar (1) · Jia Fan, PhD (1) · Judith R Kroep, MD PhD (1) · Lizza Hendriks, MD PhD (1) · Loren K Mell (1) · Maximilian Diehn, MD (1)
PMID 32615102, PMID 33358660, PMID 34499875, PMID 36600534, PMID 39551064, PMID 39615497, PMID 40966692, PMID 42335416
U10CA180820 (4), U10CA180868 (4), U10CA180888 (3), 2018 (1), 2023 (1), U10CA021661 (1)